Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

140.82 -2.26 (-1.58%)
Streaming Delayed Price Updated: 11:47 AM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 90,394
Open 143.75
Bid (Size) 140.65 (2)
Ask (Size) 141.16 (1)
Prev. Close 143.08
Today's Range 140.17 - 144.00
52wk Range 122.80 - 219.34
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Via Benzinga
Peering Into Krystal Biotech's Recent Short Interest
Via Benzinga

Performance

YTD
-10.0%
-10.0%
1 Month
+2.8%
+2.8%
3 Month
-15.2%
-15.2%
6 Month
-9.6%
-9.6%
1 Year
-26.4%
-26.4%

More News

Read More
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Via The Motley Fool
Topics Artificial Intelligence
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
What Does the Market Think About Krystal Biotech?
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Is the Market Bullish or Bearish on Krystal Biotech?
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
The Analyst Verdict: Krystal Biotech In The Eyes Of 12 Experts
Via Benzinga
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Via MarketBeat
Topics Earnings
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
A Glimpse Into The Expert Outlook On Krystal Biotech Through 9 Analysts
Via Benzinga
Earnings Scheduled For February 19, 2025
Via Benzinga
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Via Benzinga
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Looking Into Krystal Biotech's Recent Short Interest
Via Benzinga
(KRYS) - Analyzing Krystal Biotech's Short Interest
Via Benzinga
Eliminating Some Screened Stocks
Via Talk Markets
Topics Stocks / Equities

Frequently Asked Questions

Is Krystal Biotech, Inc. - Common Stock publicly traded?
Yes, Krystal Biotech, Inc. - Common Stock is publicly traded.
What exchange does Krystal Biotech, Inc. - Common Stock trade on?
Krystal Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Krystal Biotech, Inc. - Common Stock?
The ticker symbol for Krystal Biotech, Inc. - Common Stock is KRYS on the Nasdaq Stock Market
What is the current price of Krystal Biotech, Inc. - Common Stock?
The current price of Krystal Biotech, Inc. - Common Stock is 140.82
When was Krystal Biotech, Inc. - Common Stock last traded?
The last trade of Krystal Biotech, Inc. - Common Stock was at 07/07/25 11:47 AM ET
What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
The market capitalization of Krystal Biotech, Inc. - Common Stock is 3.13B
How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
Krystal Biotech, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.